(Q40897021)

24 September 2017

Oligodendroglia are protected from antibody-mediated complement injury by normal immunoglobulins ("IVIg"). (English)

1 reference

24 September 2017

1 reference

Stangel M

1

1 reference

PubMed ID

10696915

24 September 2017

Compston A

series ordinal

2

1 reference

PubMed ID

10696915

24 September 2017

Scolding NJ

series ordinal

3

1 reference

24 September 2017

1 March 2000

1 reference

Journal of Neuroimmunology

24 September 2017

1 reference

24 September 2017

103

1 reference

24 September 2017

195-201

1 reference

24 September 2017

2

1 reference

Intravenous immunoglobulin treatment of experimental T cell-mediated autoimmune disease. Upregulation of T cell proliferation and downregulation of tumor necrosis factor alpha secretion

24 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2899%2900241-6

7 January 2021

Intravenous immunoglobulin treatment in multiple sclerosis. Effect on relapses.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2899%2900241-6

7 January 2021

Targeting of IgMkappa antibodies to oligodendrocytes promotes CNS remyelination.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2899%2900241-6

7 January 2021

High-dose intravenous immunoglobulin exerts its beneficial effect in patients with dermatomyositis by blocking endomysial deposition of activated complement fragments

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2899%2900241-6

7 January 2021

Randomised placebo-controlled trial of monthly intravenous immunoglobulin therapy in relapsing-remitting multiple sclerosis. Austrian Immunoglobulin in Multiple Sclerosis Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2899%2900241-6

7 January 2021

Migration of oligodendrocyte precursors on astrocytes and meningeal cells

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2899%2900241-6

7 January 2021

The effects of intravenous immune globulin on complement-dependent immune damage of cells and tissues

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2899%2900241-6

7 January 2021

Identification of autoantibodies associated with myelin damage in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2899%2900241-6

7 January 2021

Normal human immunoglobulins for intravenous use (IVIg) delay hyperacute xenograft rejection through F(ab')2-mediated anti-complement activity

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2899%2900241-6

7 January 2021

CG-4, a new bipotential glial cell line from rat brain, is capable of differentiating in vitro into either mature oligodendrocytes or type-2 astrocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2899%2900241-6

7 January 2021

CNTF protection of oligodendrocytes against natural and tumor necrosis factor-induced death.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2899%2900241-6

7 January 2021

Distinct patterns of multiple sclerosis pathology indicates heterogeneity on pathogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2899%2900241-6

7 January 2021

Preparation of separate astroglial and oligodendroglial cell cultures from rat cerebral tissue

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2899%2900241-6

7 January 2021

Do Antibodies Stimulate Myelin Repair in Multiple Sclerosis?

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2899%2900241-6

7 January 2021

In vitro inhibitory activity of tumor necrosis factor alpha and interleukin-2 of human immunoglobulin preparations

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2899%2900241-6

7 January 2021

Mechanisms of damage to myelin and oligodendrocytes and their relevance to disease

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2899%2900241-6

7 January 2021

Inhibition of Complement-Mediated Red Cell Lysis by Immunoglobulins is Dependent on the IG Isotype and its Cl Binding Properties

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2899%2900241-6

7 January 2021

Normal immunoglobulin G protects against experimental allergic encephalomyelitis by inducing transferable T cell unresponsiveness to myelin basic protein.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2899%2900241-6

7 January 2021

Acceleration in the rate of CNS remyelination in lysolecithin-induced demyelination.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2899%2900241-6

7 January 2021

Intravenous immunoglobulins for therapeutic use contain anti-idiotypes against xenophile antibodies and prolong discordant graft survival

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2899%2900241-6

7 January 2021

Normal rat serum cytotoxicity against syngeneic oligodendrocytes. Complement activation and attack in the absence of anti-myelin antibodies.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2899%2900241-6

7 January 2021

Intravenous immunoglobulin G reduces MRI activity in relapsing multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2899%2900241-6

7 January 2021

Immunoglobulins for intravenous use inhibit TNF alpha cytotoxicity in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2899%2900241-6

7 January 2021

Polyclonal immunoglobulins for intravenous use do not influence the behaviour of cultured oligodendrocytes.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2899%2900241-6

7 January 2021

Mechanisms of high-dose intravenous immunoglobulins in demyelinating diseases

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2899%2900241-6

7 January 2021

Multiple sclerosis: in situ evidence for antibody- and complement-mediated demyelination.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2899%2900241-6

7 January 2021

Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2899%2900241-6

7 January 2021

10.1016/S0165-5728(99)00241-6

Identifiers

DOI

1 reference

24 September 2017

1 reference

PubMed ID

10696915